SZSE Ticker: 300204

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

舒泰神(北京)生物制药股份有限公司

舒泰神

STAIDSON BIO

Listing Date: 2011-04-15

Board: GEM

Industry Classification: Manufacturing

Shutaishen (300204.SZ) shareholder Xiangtang Group has reduced its holdings by about 5%

Post date May 14, 2022 — 12:00 Post Lock

Shu Taishen: The company's production and operation activities are normal_Finance Bei EHZ / Financial Diamond Value Drive

Post date May 14, 2022 — 11:28 Post Lock

Financial Associated Press May 9 Morning Post (Monday)

Post date May 9, 2022 — 07:40 Post Lock

Financial Associated Press May 9 Morning Post (Monday) New Crown in Yuhua District, Urbanization Industrial Park jqknews

Post date May 9, 2022 — 07:40 Post Lock

Observation: The first results of the industrial integration layout are seen, and Saito Bio is worthy of attention

Post date May 6, 2022 — 20:48 Post Lock

In 2021, A-share R&D expenses will exceed 1,200 billion yuan, and pharmaceutical and biological companies are "most invested"_Shenzhen Hotline

Post date May 6, 2022 — 11:48 Post Lock

In 2021, A-share R&D expenses will exceed 1.2 trillion yuan, and pharmaceutical and biological companies are "most invested"

Post date May 6, 2022 — 06:50 Post Lock

Shu Taishen: We hold global rights to STSP-0601

Post date April 29, 2022 — 00:10 Post Lock

Shutai Shenchuang has made the biggest loss since its listing. Can the new crown intensive treatment drug become a revenue-generating "dark horse"? ｜Hexun exposed financial report and financial channel Rongyi Information Network

Post date April 22, 2022 — 02:16 Post Lock

Shu Taishen: 300204 Shu Taishen Investor Relations Activity Record Form 20220420- CFi.CN Zhongcai.com

Post date April 20, 2022 — 22:27 Post Lock

Shu Taishen: 300204 Shu Taishen Research Minutes 20220420- CFi.CN Zhongcai Network

Post date April 20, 2022 — 22:27 Post Lock

The main capital of 4.355 billion yuan is withdrawn from the pharmaceutical and biological sector today – yqqlm

Post date April 20, 2022 — 18:36 Post Lock

Shu Taishen: BDB-001, STSA-1002, STSA-1005 projects are in progress

Post date April 20, 2022 — 18:16 Post Lock

Take the pulse of the A-share annual report: Who is engaged in R&D? Central enterprises are the main force, and innovative drugs are willing to "spend money"

Post date April 20, 2022 — 15:30 Post Lock

Quarterly report: Losses of 10 shares expanded and 1 share deducted non-net profit 250 million CFi.CN Zhongcai Network

Post date April 20, 2022 — 11:49 Post Lock

The concept of new crown drug treatment continued to decline in the afternoon, and many stocks fell more than 7%

Post date April 19, 2022 — 15:30 Post Lock

Sector changes, the National Medical Insurance Bureau said that it will continue to reduce the price of therapeutic drugs. The new crown drug treatment concept stocks continued to decline in the afternoon.

Post date April 19, 2022 — 15:29 Post Lock

[News] Shu Taishen Announces Annual Report CFi.CN

Post date April 19, 2022 — 01:31 Post Lock

Shu Taishen (300204.SZ) released its first-quarter results, with a net loss of 24.4095 million yuan, an increase of 22.61%.

Post date April 19, 2022 — 00:31 Post Lock

Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui_Individual Stock Information_Market Gold Online

Post date April 19, 2022 — 00:07 Post Lock

Want to see more data? Registered subscribers can see all the data.